Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PROCEPT BioRobotics ( (PRCT) ) just unveiled an update.
On September 15, 2025, PROCEPT BioRobotics Corporation’s Compensation Committee approved modifications to the Change of Control and Severance Agreement for executive officers below the CEO level. These changes include extending the severance period, clarifying performance-based award accelerations, and altering cash payment timings, aiming to better align executive compensation with market standards.
The most recent analyst rating on (PRCT) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates a bearish trend, further weighing on the score. While the earnings call provided positive revenue growth and guidance, concerns over leadership changes and ongoing losses remain. Valuation metrics are weak due to negative earnings and lack of dividends.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
PROCEPT BioRobotics Corporation operates in the medical technology industry, focusing on the development of innovative robotic solutions for surgical procedures.
Average Trading Volume: 1,116,408
Technical Sentiment Signal: Sell
Current Market Cap: $2.07B
See more data about PRCT stock on TipRanks’ Stock Analysis page.